Defunct Company
Total Trials
12
As Lead Sponsor
9
As Collaborator
3
Total Enrollment
560
NCT02605083
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 3, 2015
Completion: Mar 22, 2019
NCT02937675
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Start: Feb 8, 2017
Completion: Apr 4, 2019
NCT03258398
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
Phase: Phase 2
Start: Sep 18, 2017
Completion: May 13, 2019
NCT03318562
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Start: Nov 21, 2017
Completion: Jan 22, 2019
NCT03616834
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Start: Jul 25, 2018
Completion: Jun 30, 2021
NCT03690141
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Start: Nov 27, 2018
Completion: Apr 27, 2020
NCT03675893
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Role: Collaborator
Start: Dec 24, 2018
Completion: Aug 1, 2031
NCT04092673
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Start: Oct 25, 2019
Completion: Mar 31, 2025
NCT04261218
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer
Phase: Phase 1
Start: Aug 25, 2020
Completion: Jul 4, 2022
NCT04622007
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Start: Jun 2, 2021
Completion: Dec 9, 2024
NCT04632381
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
Start: Jul 1, 2021
Completion: Sep 22, 2023
NCT05101564
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Start: Mar 20, 2023
Completion: Dec 31, 2026